Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping-Reference-Cited by-同舟云学术

Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping

Published:2017-06-22 Issue:29 Volume:8 Page:46756-46768
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Jesinghaus Moritz¹²,Steiger Katja¹,Slotta-Huspenina Julia¹,Drecoll Enken¹,Pfarr Nicole¹,Meyer Petra¹,Konukiewitz Björn¹,Bettstetter Marcus³,Wieczorek Kathrin⁴,Ott Katja⁵,Feith Markus⁶,Langer Rupert⁷,Weichert Wilko¹²,Specht Katja¹,Boxberg Melanie¹

Affiliation:

1. Institute of Pathology, Technical University of Munich, Munich, Germany

2. German Cancer Consortium, Partner Site Munich, Munich, Germany

3. Molecular Pathology South-Bavaria, Munich, Germany

4. Institute of Pathology, University of Heidelberg, Heidelberg, Germany

5. RoMED Surgical Clinic, Rosenheim, Germany

6. Department of Surgery, Technical University of Munich, Munich, Germany

7. Institute of Pathology, University of Bern, Bern, Switzerland

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12);OncoImmunology;2024-06-24

2. Synergistic effects of Ω-3 polyunsaturated fatty acid supplementation and programmed cell death protein 1 blockade on tumor growth and immune modulation in a xenograft model of esophageal cancer;Clinical Nutrition ESPEN;2024-06

3. ISG15/GRAIL1/CD3 axis influences survival of patients with esophageal adenocarcinoma;JCI Insight;2024-05-23

4. Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma;Frontiers in Immunology;2023-02-20

5. Research Progress of PD-1/PD-L1 Signaling Pathway in Esophageal Squamous Cell Carcinoma;Advances in Clinical Medicine;2023